<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>4
<FILENAME>sinovacexh99_3.txt
<DESCRIPTION>SINOVAC BIOTECH 6K, PRESS RELEASE 8.13.04
<TEXT>






EXHIBIT 99.3
------------


                              SINOVAC BIOTECH LTD.
                              --------------------
                    CLARIFIES FURTHER ON APPLICATION TO AMEX
                    ----------------------------------------

BEIJING, August 13, 2004 - Sinovac Biotech Ltd. ("Sinovac", "the Company") (NASD
OTC-BB:  SNVBF) has filed application for listing on the American Stock Exchange
("AMEX").  The American  Stock  Exchange is the second  largest  equity  trading
floor-based exchange in the United States.  Sinovac management believes that the
Company  meets both the  quantitative  and  qualitative  criteria  required  for
listing,  as outlined  below.  The Company does wish to clarify  that  Sinovac's
application  is currently  under  review and has not yet been  approved by AMEX.
Sinovac  has  taken  the  steps to meet  all the  necessary  requirements  to be
included  on the  AMEX.  On 30  June  2004,  Sinovac  filed  its  20F  financial
statements for the full fiscal year 2003. Most recently, in accordance with AMEX
corporate  governance  standards,  Sinovac has appointed a new audit  committee,
comprised of Dr. K.K.  Ong,  Mr.  Simon J.  Anderson and Mr. Hao You in order to
ensure that the audit  committee  is  comprised  entirely  of expert,  impartial
directors.

If approved for listing on the AMEX,  Sinovac  management feels that the Company
would benefit from greater accessibility to institutional  investment,  improved
share price stability and liquidity, and broader investor awareness.

The American Stock Exchange has established certain quantitative and qualitative
standards  for the  initial  listing  of  foreign  companies.  Sinovac  has made
application  under  Standard  3,  which  requires  the  following   quantitative
standards:

Shareholders' equity                $4 million
Total market capitalization         $50 million
Distribution                        800 public shareholders and 500,000 shares
                                    publicly held
                                    OR
                                    400 public shareholders and 1 million shares
                                    publicly held
                                    OR
                                    400 public shareholders, 500,000 shares
                                    publicly held, and average daily trading
                                    volume of 2,000 shares for previous 6 months
Market value public float           $15 million

Sinovac currently has shareholders' equity of approximately US $10 million. At a
$3.25 share price, the Company has a $113 million market  capitalization.  As of
August 2004, Sinovac has over 4,100 shareholders.  Finally,  the market value of
the freely tradeable public float is currently over $34 million.  Thus,  Sinovac
management  believes  that it  currently  meets the  quantitative  criteria  for
listing on the American Stock Exchange.

In further evaluating a company's eligibility for listing on AMEX, the following
qualitative  factors are also  considered:  the nature of a company's  business,
market for its products,  reputation of its  management,  historical  record and
pattern of growth, financial integrity,  demonstrated earnings power, and future
outlook.  At this time,  the  Company  believes  that it has  submitted  all the
relevant  documentation  to AMEX in order for the exchange to make an assessment
of whether  Sinovac is eligible for listing.  Furthermore,  management  believes
that the Company has  demonstrated  that it possesses the  qualitative  criteria
that the AMEX requires in its listed companies.

ABOUT SINOVAC BIOTECH LTD.
--------------------------

Sinovac    Biotech   Ltd.    specializes    in   the   research,    development,
commercialization,  and sales of human vaccines for infectious illnesses such as
Hepatitis A and Hepatitis B, influenza and "SARS". Sinovac is one of the leading
emerging  biotechnology  companies in China. Working closely with Chinese public
health  officials,  Sinovac  focuses on  manufacturing  and marketing  human-use
vaccines and related  products,  and currently markets its vaccine for Hepatitis
A.  Sinovac  is the first and  currently  the only  company in the world to have
commenced human clinical trials for a vaccine to prevent SARS.

For further  information  please refer to the Company's  filings with the SEC at
www.sec.gov or refer to Sinovac's website at www.sinovac.com.
-----------                                  ---------------




<PAGE>






Contact: Sinovac Investor Relations at (888) 888 8312 or (604) 684-5990 or email
to info@sinovac.com.
   ----------------




THIS NEWS RELEASE MAY INCLUDE  FORWARD-LOOKING  STATEMENTS WITHIN THE MEANING OF
SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES  SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED,  WITH
RESPECT  TO  ACHIEVING  CORPORATE  OBJECTIVES,   DEVELOPING  ADDITIONAL  PROJECT
INTERESTS,   SINOVAC'S   ANALYSIS  OF   OPPORTUNITIES  IN  THE  ACQUISITION  AND
DEVELOPMENT  OF VARIOUS  PROJECT  INTERESTS  AND CERTAIN  OTHER  MATTERS.  THESE
STATEMENTS  ARE MADE UNDER THE "SAFE  HARBOR"  PROVISIONS  OF THE UNITED  STATES
PRIVATE  SECURITIES  LITIGATION  REFORM  ACT  OF  1995  AND  INVOLVE  RISKS  AND
UNCERTAINTIES  WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER  MATERIALLY FROM THOSE
IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.




</TEXT>
</DOCUMENT>
